BioAtla (BCAB) Long-Term Debt Issuances (2020)

BioAtla's (BCAB) quarterly Long-Term Debt Issuances came in at $2.2 million in Q2 2020, up 350.0% quarter-over-quarter from $500000.0 in Q1 2020.

BioAtla (BCAB) Long-Term Debt Issuances (2020) Analysis & Trends

BioAtla's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $2.2 million for Q2 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $2.2 million in Q2 2020; TTM through Mar 2021 was $2.2 million, a N/A change from a year earlier, with the FY2020 full-year figure at $2.8 million, down 31.25% from the prior year.
Long-Term Debt Issuances climbed to $2.2 million in Q2 2020 per BCAB's latest filing, from $500000.0 in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $2.2 million in Q2 2020 and bottomed at $500000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BioAtla	5.74 Mn	5.74 Mn	-	-

Download Data